Taysha Gene Therapies, Inc. TSHA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s debt-to-equity?
- Taysha Gene Therapies, Inc. (TSHA) reported debt-to-equity of 0.3× in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s debt-to-equity changed year-over-year?
- Taysha Gene Therapies, Inc.'s debt-to-equity decreased by 71.1% year-over-year, from 1.1× to 0.3×.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s debt-to-equity has grown at a -7.6% compound annual growth rate (CAGR), from 0.4× to 0.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.